Showing 7711-7720 of 9115 results for "".
- La Roche-Posay Becomes the First-Ever Official Sunscreen of the US Openhttps://practicaldermatology.com/news/la-roche-posay-becomes-the-first-ever-official-sunscreen-of-the-us-open/2461314/La Roche-Posay is the official sunscreen partner of the US Open. Beginning with this year's US Open, La Roche-Posay will have a sun safety education booth in the South Plaza of the USTA Billie Jean King National Tennis Center, with two additional product sampling kiosks on the
- First Patient Dosed in Phase 1b/2 Trial of Dermaliq Therapeutics's DLQ02 for PsOhttps://practicaldermatology.com/news/first-patient-dosed-in-phase-1b2-trial-of-dermaliq-therapeuticss-dlq02-for-pso/2461310/The first patient has been dosed in a Phase 1b/2a trial with DLQ02, a topical calcineurin inhibitor, Dermaliq Therapeutics, Inc. reports. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ02 in patients with plaqu
- Pulsed-Dye Laser Reduces the Effects of Hypertrophic Scars Post-thyroidectomyhttps://practicaldermatology.com/news/pulsed-dye-laser-reduces-the-effects-of-hypertrophic-scars-post-thyroidectomy/2461308/Treatment with a 595 nm pulsed dye laser (PDL) can prevent and improve hypertrophic scars in patients with post-thyroidectomy in a cost-effective fashion, a new study shows. For the study, 19 patients with hypertrophic scars after thyroidectomy underwent
- Epidural Nerve Block with Lidocaine Leads to Clearance of Psoriatic Skin Lesionshttps://practicaldermatology.com/news/epidural-nerve-block-with-lidocaine-leads-to-clearance-of-psoriatic-skin-lesions/2461297/Use of an epidural nerve block with lidocaine leads to clearance of psoriatic skin lesions, according to a novel proof-of-concept study in the Journal of Investigative Dermatology. “Case studies have shown that psoriasis patients have experienced significant symptom
- FDA Cracks Down on Three Companies for Selling Unapproved New Drugs for Mole and Skin Tag Removalhttps://practicaldermatology.com/news/fda-cracks-down-on-three-companies-for-selling-unapproved-new-drugs-for-mole-and-skin-tag-removal/2461294/The U.S. Food and Drug Administration issued three warning letters to three companies, including Amazon, for selling unapproved products for removing moles and skin tags, in violation of the Federal Food, Drug, and Cosmetic Act (FD&C Act). There are no FDA-appr
- Pulse Biosciences Scores FDA 510(k) Clearance of Expanded Energy Settings for CellFX Systemhttps://practicaldermatology.com/news/pulse-biosciences-scores-fda-510k-clearance-of-expanded-energy-settings-for-cellfx-system/2461289/The U.S. Food and Drug Administration (FDA) gave 510(k) clearance tp expanded energy settings for use with Pulse Biosciences, Inc.’s CellFX System treatments tips in dermatology. “Pulse Biosciences is dedicated to providing dermatologists a superior solution for the treatmen
- NRS Survey: Persistent Facial Redness Named Most Common and Bothersome Sign of Rosaceahttps://practicaldermatology.com/news/nrs-survey-persistent-facial-redness-is-the-most-common-and-bothersome-sign-of-rosacea/2461285/The great majority of rosacea patients have experienced persistent facial redness, and most of them report it is the most frequently bothersome sign they face, according to a recent National Rosacea Society (NRS) survey on rosacea redness sponsored by EPI Health. Furthermore, two-
- Survey: Chronic Hive Patients Unsatisfied with Quality of Life, Carehttps://practicaldermatology.com/news/survey-chronic-hive-patients-unsatisfied-with-quality-of-life/2461271/Only one-fourth of patients with chronic hives are satisfied with their current quality of life, according to a recent survey conducted by
- Novan's Berdazimer Gel Performs Well in Phase 3 for Molluscum: Studyhttps://practicaldermatology.com/news/novans-berdazimer-gel-performs-well-in-phase-3-for-molluscum-study/2461269/Berdazimer gel, 10.3% from Novan, Inc., significantly out-performed placebo for the treatment of molluscum, according to results of the B-SIMPLE 4 pivotal Phase 3 clinical study published in JAMA Dermatology</
- Lauren Miller, MPAS, PA-C Begins Term as SDPA Presidenthttps://practicaldermatology.com/news/lauren-miller-mpas-pa-c-begins-term-as-sdpa-president/2461267/Lauren Miller, MPAS, PA-C is president of the Society of Dermatology Physician Assistants Board of Directors. Ms. Miller, a DermPA™ with Dermatology Specialists in Gadsden, AL, will serve a one-year term leading the nine-member elected board. “I am honored and humbled t